In a phase 2 trial (ALTA), brigatinib exhibited clinical efficacy in patients with ALK+ NSCLC refractory to crizotinib, with an independent review committee (IRC)‐assessed objective response rate (ORR) of 56%, intracranial ORR of 67%, and median progression‐free survival (PFS) of 16.7 months for patients treated with a dose of 180 mg (after a 7‐day 90 mg lead‐in).10 The gene discussed is ALK; the disease is non-small cell lung carcinoma.